Published in final edited form as:

J Med Chem. 2012 August 23; 55(16): 7262–7272. doi:10.1021/jm300833h.

Discovery of a *Plasmodium falciparum* glucose-6-phosphate dehydrogenase 6- phosphogluconolactonase inhibitor (*R,Z*)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-(2-fluorobenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxamide (ML276) that reduces parasite growth *in vitro*

Janina Preuss^{†,‡,§,¶}, Patrick Maloney^{||,¶}, Satyamaheshwar Peddibhotla^{||,¶}, Michael P. Hedrick^{§,¶}, Paul Herschberger^{||,¶}, Palak Gosalia[§], Monika Milewski[§], Yujie Linda Li[§], Eliot Sugarman^{||}, Becky Hood^{||}, Eigo Suyama^{||}, Kevin Nguyen^{||}, Stefan Vasile^{||}, Eduard Sergienko[§], Arianna Mangravita-Novoli^{||}, Michael Vicchiarelli^{||}, Danielle McAnally^{||}, Layton H. Smith^{||}, Gregory P. Roth^{||}, Jena Diwan[§], Thomas D.Y. Chung[§], Esther Jortzik[‡], Stefan Rahlfs[‡], Katja Becker^{‡,*}, Anthony B. Pinkerton^{*,§}, and Lars Bode^{†,*}

[†]Department of Pediatrics, University of California, San Diego, La Jolla, California 92037, USA

[‡]Biochemistry and Molecular Biology, Interdisciplinary Research Center, Justus-Liebig-University, Ludwigstrasse 23, 35390 Giessen, Germany

[§]Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, La Jolla, CA 92037

^{||}Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute, Orlando, FL 32827, USA

Abstract

A high throughput screen of the NIH's MLSMR collection of ~340,000 compounds was undertaken to identify compounds that inhibit *Plasmodium falciparum* glucose-6-phosphate dehydrogenase (*Pf*G6PD). *Pf*G6PD is essential for proliferating and propagating *P. falciparum* and differs structurally and mechanistically from the human ortholog. The reaction catalyzed by glucose-6-phosphate dehydrogenase (G6PD) is the first, rate-limiting step in the pentose phosphate pathway (PPP), a key metabolic pathway sustaining anabolic needs in reductive equivalents and synthetic materials in fastgrowing cells. In *P. falciparum* the bifunctional enzyme glucose-6-phosphate dehydrogenase-6- phosphogluconolactonase (*Pf*GluPho) catalyzes the first two steps of the PPP. Because *P. falciparum* and infected host red blood cells rely on accelerated glucose flux, they depend on the G6PD activity of *Pf*GluPho. The lead compound identified from this effort, (*R,Z*)-N-((1-ethylpyrrolidin-2-yl)methyl)-2- (2-fluorobenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxamide, **11**, (ML276), is a submicromolar inhibitor of *Pf*G6PD (IC₅₀ = 889 nM). It is completely selective for the enzyme's human isoform, displays micromolar potency (IC₅₀ = 2.6 μM) against *P. falciparum* in culture, and has good drug-like

*Corresponding authors: (K.B.) Tel: +49-641-9939121 Fax: +49-641-9939129, katja.becker@uni-giessen.de. (A.B.P.) Tel: 01-858-695-5320, apinkerton@sanfordburnham.org. (L.B.) Tel: 01-619-543-7545 Fax: 01- 619-543-7537, lbode@ucsd.edu.

[¶]These authors contributed equally to this work

Supporting Information Available

Detailed experimental procedures for the synthesis of **1b**, **1c**, **2b**, **2c**, **3b**, **3c**, **3d**, **4b**, **4c**, **4d**, **4e**, **4f**, **4g**, **4h**, **4i**, **4j**, **5a**, **5b**, **5c**, **5d**, **5e**, **5f**, **5g**, **5h**, **5i**, **5j**, **10**, **12**, **13**, **14**, **15**, **17**, **22**, **29**, **33**, **34**, **39**, **40**, **41**, **42** as well as NMR-spectra of **2a**, **3a**, **3d**, **4a**, **5a**, **5b**, **5c**, **5d**, **5e**, **5f**, **5g**, **5h**, **5i**, **5j**, **10**, **11** (methanol-d₄), **11** (methanol-d₄), **12**, **13**, **14**, **15**, **17**, **22**, **29**, **33**, **34**, **39**, **40**, **41**, **42** are reported in the Supplementary Information. This material is available free of charge via the Internet at <http://pubs.acs.org>

properties, including high solubility and moderate microsomal stability. Studies testing the potential advantage of inhibiting *PfG6PD* *in vivo* are in progress.

Keywords

6-phosphogluconolactonase; glucose-6-phosphate; glucose-6-phosphate dehydrogenase; highthroughput screening; malaria; pentose phosphate pathway; *Plasmodium*; redox metabolism; benzothiazinone

INTRODUCTION

In 2010, around 1.2 million people died from malaria infections.¹ Severe forms of the disease are mainly caused by *Plasmodium* parasites of the species *falciparum*, which are transmitted to the human host by female *Anopheles* mosquitoes.² *P. falciparum* parasites have infected humans for thousands to millions of years,^{3,4} and yet malaria eradication has not been possible due to the parasites' ability to develop resistance to most antimalarial drugs.⁵ To date, no vaccine against malaria is available,⁶ and infections are treated with drugs commonly targeting the blood stage of the parasite.⁷ The most common clinically used antimalarial drugs belong to seven classes, namely 4-aminoquinolines such as chloroquine and amodiaquine, arylaminoalcohols such as quinine and mefloquine, 8-aminoquinolines such as primaquine, artemisinins such as artemether and artesunate as well as synthetic peroxides such as tri- and tetraoxanes⁸, antifolates such as sulfadoxine and pyrimethamine, inhibitors of the respiratory chain such as atovaquone, and antibiotics.^{9,10} The occurrence of drug-resistant *P. falciparum* strains^{11–13} as well as side effects from drug administration^{14,15} resulted in the current WHO recommendation to use artemisinin-based combination therapies to treat *P. falciparum* malaria.¹⁶ However, recent reports of artemisinin resistances^{17–19} again create an urgent need for new anti-malarial drugs. Based on several findings, the enzyme glucose-6-phosphate dehydrogenase 6-phosphogluconolactonase of *P. falciparum* (*PfGluPho*) has emerged as an intriguing new target for anti-malarial drug development.²⁰ Deficiency in human glucose-6-phosphate dehydrogenase (hG6PD), which affects around 330 million people worldwide,²¹ is associated with protection from severe malaria infections.^{22–24} It is suggested that both hG6PD and *PfGluPho* play an important role in *Plasmodium* development and survival.^{20,22,25} *PfGluPho* is the key enzyme of the parasitic pentose phosphate pathway (PPP), which is supposed to be the major NADPH source (reviewed by Preuss *et al.*²⁶) for these parasites highly sensitive to oxidative stress.²⁷ A previous study showed that *P. falciparum*-infected red blood cells (IRBC) present an increased PPP activity compared to non-infected ones, 80% of which is caused by *Plasmodium*'s PPP.²⁵ Moreover, silencing of *PfGluPho* with RNA interference (RNAi) stopped parasite development at the trophozoite stage.²⁸ Although Baum *et al.* reported in 2009 that *P. falciparum* lacks an RNAi machinery,²⁹ Lopez- Barragan *et al.* recently reported that antisense RNA may be an important factor in *P. falciparum*'s regulation of gene expression,³⁰ strengthening the results of the previous RNAi-based study. Additionally, *PfGluPho* presents considerable structural differences compared to hG6PD, potentially allowing selective targeting.^{31,32}

Herein we describe the high-throughput screening (HTS) of 348,911 compounds in the NIH's Molecular Libraries Small Molecule Repository (MLSMR) collection (<http://mli.nih.gov/mli/compound-repository/mlsmr-compounds>) against *PfGluPho* and a subsequent structure-activity relationship (SAR) study of a class of benzothiazinone hits obtained from the screen. Optimization of the screening hits resulted in the discovery of (*R,Z*)-*N*-((1-ethylpyrrolidin-2-yl)methyl)- 2-(2-fluorobenzylidene)-3-oxo-3,4-dihydro-2H-benzo[*b*][1,4]thiazine-6-carboxamide, **11**, (ML276),³³ which inhibited *PfGluPho* selectively

over hG6PD and inhibited *P. falciparum* growth *in vitro* with an IC₅₀ in the low micromolar range. Compound **11** represents the first reported selective *Pf*GluPho inhibitor and therefore could provide a basis for future drug design of new antimalarial therapeutics.

RESULTS AND DISCUSSION

High Throughput Screen

In a primary screening approach, the MLSMR compound library (~350,000 compounds) was screened at a concentration of 20 μ M against *Pf*GluPho. The screening campaign resulted in the identification of 2,709 compounds that inhibited *Pf*GluPho activity 59%, corresponding to a hit rate of 0.8%. Of these, 2,429 were available from the MLSMR collection and were retested in triplicates at a concentration of 20 μ M, resulting in 817 compounds inhibiting *Pf*GluPho 50%, about 34% of the samples. To exclude samples that interfere with the coupled resazurin/diaphorase system used in our study,³⁴ active compounds were run against a diaphorase inhibition assay at a concentration of 20 μ M. Of the compounds tested, 230 inhibited the diaphorase reaction and thus were discarded as artifacts. The remaining 587 active compounds were further tested in dose response in the *Pf*GluPho assay and an hG6PD counter-screen. As a result, 488 compounds presented IC₅₀ values 20 μ M vs. *Pf*GluPho, and only 39 of the compounds were active against hG6PD. For final confirmation, the compounds were tested in an orthogonal assay that did not rely on the resazurin and diaphorase coupled system. Based on the initial slope of the reaction, around 50% of the compounds were confirmed to inhibit *Pf*GluPho with an IC₅₀ 80 μ M. Several series of compounds were identified, of which a group of benzothiazinones was most promising based on their potency and selectivity. Detailed information is available in the PubChem database (AIDs 504690, 504753, 504863, 504862, 504765, 504792, 540252, 540269).

Synthesis

The synthesis of the benzothiazinone-derived compounds described herein was accomplished in 4–5 steps as outlined in Scheme 1.³⁵ Starting from 4-fluoro-3-nitrobenzoic acid or the esters (**1a–c**), nucleophilic substitution of the fluorine substituent with ethyl thioglycolate under basic conditions provided thioethers (**2a–c**). Reductive cyclization mediated by iron in acetic acid provided benzothiazinones (**3a–c**). 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI)-mediated coupling of **3a** with 2-aminomethyl-1-ethylpyrrolidine afforded amide **3d**. The first point of diversity was introduced by condensation of benzothiazinones (**3a–c**) with a range of aromatic aldehydes resulting in intermediates (**4a–j**). Coupling of intermediates (**4a–j**) with 2-aminomethyl-1-ethylpyrrolidine resulted in the corresponding amides **5a–j** (Scheme 1). The styryl moiety in the intermediate **4a** was reduced with sodium borohydride in the presence of cobalt chloride, and the resulting acid was converted to amide **10** (Scheme 2). A second point of diversity resulted from amide synthesis starting from **4a** using diverse amines to provide the amides **10–15**, **17**, **22**, **29**, **33**, **34**, **39–42** (Scheme 2). All final compounds were obtained in moderate yields and high purity needed to support SAR studies.

Structure Activity Relationships (SAR)

Three main assays were utilized to direct the SAR efforts. The primary SAR-driving assay was the dose response, resazurin/diaphorase-coupled *Pf*GluPho assay, with the hG6PD assay serving as the counterscreen to ascertain specificity. None of the compounds from this series showed any activity in the hG6PD counterscreen (>80 μ M) and thus were considered specific for the *P. falciparum* enzyme. The orthogonal *Pf*GluPho assay, which relied on the direct detection of NADPH, was used to further confirm activity in the absence of the coupled resazurin/diaphorase system. Of the 156 substituted benzothiazinones tested in the

high throughput screen, only five were confirmed active by dose response. All were inactive ($IC_{50} > 80 \mu M$) against hG6PD. These structures are represented in Table 1. The structural features of these active benzothiazinones that separate them from those that were either inactive or failed confirmation in dose response include: 1) the amide side chain contains a basic alkylamine; 2) the nitrogen in the benzothiazinone ring is not alkylated; and 3) the sulfur exists as a sulfide (Figure 1).

From this preliminary SAR, we focused on further optimization of the scaffold. Specifically, we examined a wide range of amide substitutions as well as substitution around the pendant aryl ring. The general SAR strategy is depicted in Figure 2.

Exploration of the styryl SAR was initiated by maintaining the preferred 1-ethyl-2-aminomethylpyrrolidine moiety from the HTS data and is summarized in Table 2. The primary hit **5a**, identified during the HTS and subsequent hit confirmation, was resynthesized as described in Scheme 1. It was equipotent to the purchased compound (Entry **5a**, Tables 1 and 2). 1H NMR data of the purchased sample and the synthesized sample of **5a** were identical. The *Z*-geometry around the styryl portion was assigned based on comparison to previously reported NMR data.³⁶

A variety of substituted styryl analogs were synthesized; however, the potency range was only affected by 7-fold. The 2-fluoro substituent is important for activity, as the analog without any aryl substituent was ~ 4-fold less active (entry **5a** vs. **5b**, Table 2). Interestingly, neither the position nor the electronics of the substituent dramatically affected the observed potency. For example, analogs containing the 2-, 3-, or 4-fluoro substitution (entries **5a**, **5e**, and **5f**, Table 2) were essentially equipotent. Replacement of the 2-fluoro substituent with 2-chloro did not significantly affect the potency, but replacement with electron-rich 2-methyl or 2-methoxy groups decreased potency by 3-fold and 5-fold respectively (Entries **5a**, **6**, **5c**, and **5d**, Table 2). Fused ring systems such as 1-naphthyl and 2-naphthyl (Entries **5i** and **5j**, Table 2) also slightly lowered potency. The unsubstituted phenyl and the 2-methoxy analogs (Entries **5b** and **5d**, Table 2) were the least preferred of the synthesized analogs.

While the SAR around the styryl moiety may appear to minimally affect potency, its presence was required for activity. When the styryl group was replaced with phenethyl or removed entirely, a complete loss of activity resulted (**5a** vs. **3d** & **10**, Table 3).

The SAR of the alkylamino side chain proved to be much more stringent than the styryl region, with a strong preference for 2-aminomethyl pyrrolidines. Potency was maintained within 5-fold whether the nitrogen of the pyrrolidine ring was substituted with ethyl, propyl, or was unsubstituted (Entries **5a**, **13** and **15**, Table 4). The *t*-butoxycarbonyl derivative proved inactive, consistent with observations from the HTS (Entry **14**, Table 4). Less constrained examples such as dimethylaminoethyl, diethylaminoethyl, and dipropylaminoethyl demonstrated sharp decreases in potency (Entries **16–27**, Table 5). Attachment of pyrrolidine through nitrogen via an aminoethyl linker led to a 5-fold loss of potency, which became more pronounced as the ring was expanded (Entries **8**, **9**, **28–39**, Table 6). Examples of constrained tertiary or aromatic amides proved substantially less active (Entries **40–42**, Table 6). All compounds represented in Tables 4, 5, and 6 exhibited an $IC_{50} > 80 \mu M$ against hG6PD.

Stereochemical evaluation of the 2-aminomethyl pyrrolidines led us to synthesize each enantiomer of **5a** from the corresponding commercially available chiral amines. An 8-fold preference for the *Renantiomer* versus the *S*-enantiomer was discovered (Entries **11** & **12**, Table 4). Compound **11**, (*R,Z*)-*N*-((1-ethylpyrrolidin-2-yl)methyl)-2-(2-fluorobenzylidene)-3-oxo-3,4-dihydro-2H-benzo[*b*][1,4]thiazine-6-carboxamide, was the

most potent compound identified and was therefore declared a probe. Compound **11** was selective for *Pf*GluPho over hG6PD (Figure 3).

In vitro ADME/T profiling and chemical stability

Compound **11** was evaluated in a detailed *in vitro* pharmacology screen (absorption, distribution, metabolism, excretion, toxicity (ADME/T)) as shown in Table 7. Compound **11** is highly soluble especially at lower pH, which is likely due to the presence and protonation of the alkylamino moiety. Consistent with its solubility data, **11** exhibits high permeability with increased pH of the donor compartment in a standard parallel artificial membrane permeability assay (PAMPA). When incubated with an artificial membrane that models the blood-brain barrier (BBB), **11** was highly permeable. Compound **11** had good stability in plasma, thus increasing its exposure to blood-borne parasites such as *P. falciparum*, and it was highly plasma protein bound, which may contribute to its high plasma stability. Lastly, **11** shows moderate stability in human and modest stability in mouse liver homogenates and no toxicity (>50 OM) toward Fa2N-4 immortalized human hepatocytes.

Compound **11** contains an α,β -unsaturated amide and is a potential Michael acceptor. To investigate this potential chemical liability, **11** (10 μ M, 1% DMSO) was incubated with 5 equivalents of glutathione (GSH) in PBS buffer (pH 7.4) at 23 °C. Loss of compound was monitored at different times over 18 h using RP-LCMS (Figure 4). Ethacrynic acid, a diuretic containing an α,β -unsaturated ketone, was used as a positive control since it has been previously reported to form GSH-adduct.³⁷ Loss of ethacrynic acid was observed as early as 30 minutes and was ~97% depleted in 24 h; whereas **11** remained intact for the duration of the study, indicating a lack of reactivity with nucleophiles (Figure 4). Thus, **11** represents a potential lead compound for the development of an *in vivo* probe.

Activity against *P. falciparum* in culture

Compound **11** was included in *P. falciparum* growth assays to assess its effects on blood stage parasites *in vitro*. After incubation for 72 hours, **11** gave IC₅₀ values of $2.3 \pm 0.2 \mu$ M for the chloroquine sensitive 3D7 strain and 3.7 ± 0.9 for the chloroquine resistant Dd2 strain (Figure 5).

Mechanism of Inhibition (MOI) studies

The most likely type of inhibition was determined by titrating compound and substrate/co-substrate at the same time. G6P and **11** titration revealed increasing K_m values and an $\alpha > 6.6$ with increasing compound concentration, suggesting that **11** inhibits *Pf*GluPho activity by competing with the substrate (Figure 6B). Increasing K_m and decreasing V_{max} values, and α between 1.4 and 4.7, were found when compound and co-substrate were titrated, indicating mixed-type inhibition of **11** vs. NADP⁺ (Figure 6A).

CONCLUSIONS

A series of benzothiazinones derived from an HTS of the NIH's MLSMR collection that are potent, fully selective inhibitors of *Pf*GluPho has been reported. The most potent compound in this series, **11**, has antimalarial activity against both chloroquine-sensitive and chloroquine-resistant strains. Compound **11** has reasonable *in vitro* ADME/T properties, including excellent solubility, no toxicity, good permeability, and plasma stability and moderate microsomal stability. Further work in this series is in progress to optimize the potency and ADME/T properties, which may lead to validation in *in vivo* models.

EXPERIMENTAL SECTION

HTS/Biology

Materials—G6P, resazurin, diaphorase, Tween20, MgCl₂, and BSA were obtained from Sigma, St. Louis, MO. NADP⁺ was purchased from Amresco, Solon, OH, and 1,536 well-plates from Aurora, Poway, CA.

Compound library—The Sanford-Burnham Center for Chemical Genomics' copy of the NIH Molecular Libraries Small Molecule Repository (MLSMR) consisted of 348,911 compounds when the screen was run, which were present in 1,536-well plates at a concentration of 2 mM (in DMSO). The library was stored at –80°C until first use, after which it was kept at room temperature under desiccating conditions for a period not greater than six months.

HTS

Primary Screen: The previously developed HTS assay for *PtGluPho*³⁴ was used in a 384-well plate format. This assay was slightly modified for use in 1,536-well plates and performed in the following way. A volume of 60 nL of the compounds (final 20 OM, 1% DMSO) was transferred to columns 5–48 of 1,536-well plates using the Echo Liquid Handler (LabCyte). Then 60 nL of DMSO were transferred to columns 1–4, which served as positive and negative controls. A volume of 3 µL of enzyme mix (50 mM Tris (pH 7.5), 0.005% Tween 20, 1 mg/mL BSA, 0.1 µg/mL *PtGluPho*) was added to all wells using the Kalypsys (Kalypsys Systems). To start the reaction, 3 µL substrate mix (50 mM Tris (pH 7.5), 40 µM G6P, 0.005% Tween 20, 1 mg/mL BSA, 6 µM NADP⁺, 6.6 mM MgCl₂, 2 U/mL diaphorase, 0.05 mM resazurin) were added to columns 3–48 using the Kalypsys. Substrate mix without G6P was added to columns 1–2 for positive control. The plates were centrifuged at 1,500 rpm for 1 min and incubated in the dark for 2 hours. Fluorescence of resorufin was detected at excitation 530/emission 580 nm (ex530/em580) using a Viewlux (PerkinElmer) plate reader. Data was analyzed with CBIS (Chemical and Biological Information Systems, www.cheminnovation.com) and compounds inhibiting *PtGluPho* for at least 59% were retested as described before. Retested compounds inhibiting *PtGluPho* activity 50% were further investigated.

Diaphorase counter-screen: First 12 nL of 10 mM compounds in DMSO were transferred into columns 5–48 of 1,536-well plates using the Echo Liquid Handler. Next, 12 nL of DMSO were transferred to columns 1–4 for positive and negative controls. Subsequently, 3 µL of substrate mix (50 mM Tris (pH 7.5), 0.005% Tween20, 1 mg/mL BSA, 6.6 mM MgCl₂, 0.06 mM/0.02 mM NADPH, 0.05 mM resazurin) were added to columns 1–48 using the Multidrop Combi reagent dispenser (Thermo Scientific). To initiate the reaction, 3 µL of enzyme solution (50 mM Tris (pH 7.5), 0.005% Tween 20, 1 mg/mL BSA, 6.6 mM MgCl₂, 2 U/mL diaphorase) were added to columns 3–48 with the Multidrop Combi dispenser. For the negative control, 3 µL of the enzyme solution without diaphorase were added to columns 1–2. The plates were centrifuged at 1,500 rpm for 1 min, incubated in the dark for 2 hours, and read at ex530/em590 nm. Diaphorase inhibition was analyzed using CBIS and compounds exhibiting at least 50% enzyme inhibition were assigned active status and thus not included in further experiments.

Hit confirmation in dose response—Varying volumes of compounds in DMSO (starting final concentration of 20 µM) were transferred to columns 5–48 of 1,536-well plates using the Echo Liquid Handler. DMSO was added to control and test compound wells to equilibrate DMSO concentrations across plate (final concentration of 1.0%). The

remaining assay procedures for the *Pt*GluPho assay were performed as described in 'Primary Screening.' Compounds with an IC_{50} of $\geq 20 \mu M$ were further investigated.

hG6PD counter screen—Using the Echo Liquid Handler, varying volumes of compounds (starting final concentration of $20 \mu M$) were transferred to wells of columns 5–48 of 1,536-well plates. DMSO was added to control and test compound wells to equilibrate DMSO concentrations across the plate (final concentration of 0.8%). Then 2.5 μL of enzyme solution (50 mM Tris (pH 7.5), 0.005% Tween 20, 1 mg/mL BSA, 0.05 $\mu g/mL$ hG6PD) were transferred to all wells. Following enzyme addition, 2.5 μL substrate solution (0.64 mM G6P, 50 mM Tris (pH 7.5), 0.005% Tween 20, 1 mg/mL BSA, 12 μM NADP⁺, 6.6 mM MgCl₂, 2 U/mL diaphorase, 0.28 mM resazurin) were added to columns 3–48 and solution without G6P to columns 1–2 for positive control. After 1 min of centrifugation at 1,500 rpm and 90 min incubation in the dark, fluorescence of resorufin was detected at ex530/em590 by using the Viewlux plate reader. IC_{50} values were calculated using CBIS.

Orthogonal assay—Using the Echo Liquid Handler, varying volumes of compounds were transferred to wells of columns 5–48 of 1,536-well plates. DMSO was added to control and test compound wells to equilibrate DMSO concentrations across the plate. Following compound and DMSO transfer, 2.5 μL of enzyme solution (50 mM Tris (pH 7.5), 0.005% Tween 20, 1 mg/mL BSA, 0.4 $\mu g/mL$ *Pt*GluPho) were added to all wells using a Multidrop Combi dispenser. Then 2.5 μL of substrate solution (40 μM G6P, 6 μM NADP⁺, 50 mM Tris (pH 7.5), 0.005% Tween 20, 1 mg/mL BSA, 6.6 mM MgCl₂) were added to columns 5–48, and 2.5 μL of solution without G6P were added to columns 1–4 for positive control. The plates were centrifuged and either incubated for 45 min to determine endpoints of the reaction or kinetically read at ex 340nm /em 450 nm over 45 min. The reaction rate was calculated by dividing the relative fluorescence units (RFU) by time in minutes. CBIS was used to calculate IC_{50} values, and compounds with IC_{50} s $\geq 80 \mu M$ were designated active.

Chemistry

All reactions involving air and moisture-sensitive reagents and solvents were performed under a nitrogen atmosphere using standard chemical techniques. Anhydrous solvents were purchased and freshly used from Sigma-Aldrich or EMD Biosciences. All organic reagents were used as purchased. (*R*)-(1-ethylpyrrolidin-2-yl)methanamine (Catalog no. 357000010, CAS 22795-97-7) and (*S*)-(1-ethylpyrrolidin-2-yl)methanamine (Catalog no. 367750010, CAS 22795-99-9) were purchased from Acros Organics and used without further purification. Analytical thin-layer chromatography was performed on Partisil K6F silica gel 60 A, 250 μm . Microwave-assisted reactions were performed using a CEM Discover system. ¹H and ¹³C chemical shifts are reported in δ values in ppm in the corresponding solvent. All solvents used for chromatography on the synthetic materials were Fisher Scientific HPLC grade, and the water was Millipore Milli-Q PP filtered. All NMR spectra for the synthetic materials were recorded on a Bruker Avance II 400 or DRX-500 MHz instrument. High Resolution Mass Spectrometry (HRMS) spectra were carried out on an Agilent 6224A Accurate-Mass Time-of-Flight (TOF) LC/MS system with electron spray ionization (ESI). LCMS analysis of synthetic materials was completed on a Waters Autopurification system, which consists of a 2767 sample manager, a 2545 binary gradient module, a system fluidics organizer, a 2489 UV/vis detector, and a 3100 mass detector, all controlled with MassLynx software. A Sunfire Analytical C18 5 μm column (4.6 $\times$ 50 mm) and stepwise gradient { 10% [(MeCN + 0.1% TFA) in (water + 0.1% TFA)] to 98% [(MeCN + 0.1% TFA) in (water + 0.1% TFA)] for 9 min. } was used for analytical LCMS of final compounds. The final compounds were purified by RP-HPLC on a SunFire preparative C18 column (5 μm ; 19 $\times$ 50 mm) using a stepwise gradient { 10% [(MeCN + 0.1% TFA) in (water + 0.1% TFA)] for 1 min.; 30% for 1 min.; 50% for 4 min.; 70% for 1.5 min. and 98%

for 1.5 min.}. All synthesized final compounds **5a–j** and **10–42** were determined to be 95% pure by LC-MS. Compound identity was verified by ^1H NMR and HRMS, and additionally by ^{13}C NMR for **11**. The MestReNova program was used to interpret NMR spectra.

General procedure for the synthesis of compounds 5a–j & 10–42 as illustrated by synthesis of (R, Z)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-(2-fluorobenzylidene)-3-oxo-3,4-dihydro-2Hbenzo[b][1,4]thiazine-6-carboxamide (11)

4-(2-ethoxy-2-oxoethylthio)-3-nitrobenzoic acid (2a)—4-fluoro-3-nitrobenzoic acid (**1a**) (5.55 g, 30 mmol) and sodium acetate (2.71 g, 33 mmol) were combined in a round bottom flask. Ethyl mercaptoacetate (3.62 mL, 33 mmol) and water (30 mL) were then added, and the mixture was heated under nitrogen atmosphere at 90 °C for 24 h. The reaction mixture was cooled to 23 °C and then placed in an ice bath for 10–20 min. The precipitate formed was collected by filtration, washed with water, and dried to afford **2a** as a tan solid (8.66 g, quant.) ^1H NMR (500 MHz, CDCl_3) δ 9.02 – 8.91 (m, 1H), 8.34 – 8.20 (m, 1H), 7.64 (d, J = 8.6 Hz, 1H), 4.26 (q, J = 7.1 Hz, 2H), 3.84 (s, 2H), 1.31 (t, J = 7.1 Hz, 3H); LRMS (ESI-ve): calculated for $\text{C}_{11}\text{H}_{11}\text{NO}_6\text{S}$, $[\text{M}-\text{H}] = 284.02$, observed $[\text{M}-\text{H}] = 283.99$.

3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxylic acid (3a)—**2a** (3.94 g, 13.8 mmol) and iron powder (3.08 g, 55 mmol) were suspended in glacial acetic acid (33 mL) in a round-bottom flask equipped with an air condenser under nitrogen atmosphere. The mixture was heated to 80 °C in an oil bath, during which the suspension turned reddish brown, and the temperature of the bath rose to 92 °C. After 30 minutes the temperature of the oil bath was lowered to 80 °C and maintained for 2 h. The mixture was then allowed to cool to 23 °C and stir for about 20 h and then was poured into 1N HCl solution (150 mL). After stirring the mixture for 30 minutes, the precipitate was filtered, washed extensively with water and diethyl ether, and dried to afford **3a** as a light gray solid (2.56 g, 89%). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 12.99 (s, 1H), 10.72 (s, 1H), 7.55 (s, 1H), 7.50 (d, J = 7.9 Hz, 1H), 7.42 (d, J = 7.9 Hz, 1H), 3.31 (s, 2H); LRMS (ESI-ve): calculated for $\text{C}_9\text{H}_6\text{NO}_3\text{S}$, $[\text{M}-\text{H}] = 208.01$, observed $[\text{M}-\text{H}] = 207.95$.

(Z)-2-(2-fluorobenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxylic acid (4a)—**3a** (1.2 g, 5.7 mmol), was suspended in acetic anhydride (20 mL) in a 40 mL vial. Triethylamine (2.39 mL, 17.2 mmol) and 2-fluorobenzaldehyde (1.21 mL, 11.5 mmol) were added, and the mixture was heated at 145 °C for 15 h. The reaction mixture was cooled to 23 °C, poured into 100 mL of diethyl ether, and cooled at 4 °C for 20 min. The precipitate was collected by filtration, washed with ether (25 mL), and dried to afford **4a** as a yellowish brown solid (1.28 g, 71%). ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 11.30 (s, 1H), 7.86 (s, 1H), 7.79 (t, 1H), 7.69 (d, J = 1.7 Hz, 1H), 7.55 (dd, J = 8.3, 1.7 Hz, 1H), 7.53 – 7.48 (m, 1H), 7.43 (d, J = 8.2 Hz, 1H), 7.40 – 7.33 (m, 2H); LRMS (ESI-ve): calculated for $\text{C}_{16}\text{H}_{10}\text{FNO}_3\text{S}$, $[\text{M}-\text{H}] = 314.03$, observed $[\text{M}-\text{H}] = 314.0$.

(R,Z)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-(2-fluorobenzylidene)-3-oxo-3,4-dihydro-2Hbenzo[b][1,4]thiazine-6-carboxamide (11)—**4a** (300 mg, 0.95 mmol), HOBt (193 mg, 1.43 mmol) and EDCI-HCl (274 mg, 1.43 mmol) were combined in an 8 mL vial. Dry dichloromethane (4 mL) and triethylamine (0.4 mL, 2.85 mmol) were added, and the mixture was stirred at 23 °C for 5 minutes. (R)-(1-ethylpyrrolidin-2-yl)methanamine (0.2 mL, 1.43 mmol) was added, and within a few minutes the solution became homogenous and was allowed to stir for about 15 h. The reaction mixture was then diluted with 20% methanol/dichloromethane (5 mL) and extracted with water (4 mL, 3x). The organic layer was dried over anhydrous sodium sulfate and evaporated to afford a brown residue. The

residue was purified by RP-HPLC on a SunFire preparative C18 column (5 μ m; 19 $\times$ 50 mm) using a stepwise gradient {10% [(MeCN + 0.1% TFA) in (water + 0.1% TFA)] for 1 min.; 30% for 1 min.; 50% for 4 min.; 70% for 1.5 min. and 98% for 1.5 min.}. The fractions containing the expected molecular weight were collected and freeze-dried to afford a formate salt of the product as a pale yellow solid. The solid was dissolved in dichloromethane and extracted with 25% K₂CO₃ solution (3x). The organic layer was dried over anhydrous sodium sulfate and evaporated to afford **11** as a yellowish brown solid (0.13 g, 32%). Melting Point = 194–197 °C; [α]_D = (+)–12.9 (c = 0.001, MeOH, 23 °C); ¹H NMR (500 MHz, acetic acid-*d*₄) δ 8.05 (s, 1H), 7.83 (t, *J* = 7.3 Hz, 1H), 7.60 (dd, *J* = 8.3, 1.7 Hz, 1H), 7.52 (d, *J* = 1.6 Hz, 1H), 7.44 (dd, *J* = 13.3, 6.3 Hz, 1H), 7.36 (d, *J* = 8.3 Hz, 1H), 7.31 (t, *J* = 7.5 Hz, 1H), 7.20 (t, *J* = 7.5 Hz, 1H), 3.98–3.76 (m, 4H), 3.54–3.41 (m, 1H), 3.23–3.08 (m, 2H), 2.37–2.22 (m, 1H), 2.12–2.05 (m, 3H), 1.33 (t, *J* = 7.5 Hz, 3H). For ¹H NMR in methanol-*d*₄, see ancillary information. LRMS (ESI+ve): calculated for C₂₃H₂₄FN₃O₂S, [M+H] = 426.17, observed [M+H] = 426.26; HRMS (ESI+ve): calculated for C₂₃H₂₄FN₃O₂S, [M+H] = 426.1646, observed [M+H] = 426.1631.

Activity against *P. falciparum* in culture—The chloroquine-sensitive *P. falciparum* 3D7 and the resistant Dd2 strains were cultured as described elsewhere.³⁸ Effects of PfGluPho inhibitors on *Plasmodium* parasites were tested using isotopic drug sensitivity assays,^{39,40} which are based on the incorporation of radioactive ³H-hypoxanthine. Hypoxanthine is taken up by *Plasmodium* parasites, since it is needed for nucleic acid synthesis. In brief, *P. falciparum*-infected RBCs were seeded in 96-well plates (Nunc) at a parasitemia of 0.25% (>70% ring forms) and 1.25% hematocrit in hypoxanthine-free medium. Varying concentrations of the test compounds and the control chloroquine (Sigma) were added to the wells. The parasites were incubated for 48 hours, after which 0.5 μ Ci ³H-hypoxanthine was added for a further 24 hours. The cells of each well were harvested on a glass fiber filter (Perkin-Elmer), washed, and dried. Finally, the radioactivity of each condition was detected, which is supposed to be proportional to the parasites' growth. IC₅₀ values were calculated using non-linear regression of the GraphPad Prism software.

MOI studies—PfGluPho inhibitors were mechanistically characterized as previously described.³⁴ In brief, varying G6P or NADP⁺ concentrations were prepared in a substrate solution (final assay concentration (FAC) 3.3 mM MgCl₂, 1 mM TCEP, 0.05 M Tris, for G6P titration: 5 μ M NADP⁺/for NADP⁺ titration: 25 μ M G6P) and transferred to 384-well plate. Varying compound concentrations (starting at around 8x IC₅₀) titrated in DMSO were added to the wells using the Echo Liquid Handler. Addition of an enzyme mix (FAC 0.2 μ g/mL PfGluPho, 0.005% Tween 20) started the reaction. Fluorescence of NADPH production was monitored over 10 min at ex340/em460 with a SpectraMax M5 (Molecular Devices) multiwell plate reader and the initial slope was determined with the SoftMax Pro 5.2 software (Molecular Devices). Based on the data, Lineweaver-Burk plots were created,⁴¹ and K_m and V_{max} values were calculated with the GraphPad Prism software. Additionally, α from the following rate equation was calculated using SigmaPlot (Systat Software) (Eq. (1); v=velocity, S=substrate, I=inhibitor).

$$v = \frac{V_{\max}^{\text{app}} [S]}{K_m^{\text{app}} + [S]},$$

$$\text{where } V_{\max}^{\text{app}} = \frac{V_{\max}}{(1+[I]/\alpha K_i)} \text{ and } K_m^{\text{app}} = K_m \frac{(1+[I]/K_i)}{(1+[I]/\alpha K_i)} \quad \text{Eq. (1)}$$

If Lineweaver-Burk plots intersected at the y-axis, K_m^{app} increased, and V_{max}^{app} was constant with increasing inhibitor concentrations, $\alpha = \infty$, then compounds were assigned to inhibit competitively. Lineweaver-Burk plots intersecting at the x-axis, constant K_m^{app} and decreasing V_{max}^{app} values with increasing inhibitor concentrations, and $\alpha = 1$ indicated non-

competitive inhibition. Parallel lines in Lineweaver-Burk plots, decreasing K_m^{app} and V_{max}^{app} values with increasing inhibitor concentration, and $\alpha < 1$ was characteristic for uncompetitive inhibition.⁴² Were parameters found to be between those for competitive and non-competitive inhibitors, compounds were assigned to follow mixed-type inhibition. Eq. (1)

Protocol for chemical stability (reactivity/GSH adduct formation)

Protocol: 10 μ L of compound (1 mM stock in DMSO) was added to 985 μ L PBS buffer (1x, pH = 7.4) in a capped glass vial. 5 μ L GSH solution (10 mM stock in PBS) was added to the solution, and the mixture was gently mixed on a Grant-Bio PS-M3D platform shaker at 23 °C. 20 μ L aliquots were analyzed at 0, 0.5, 1, 2, 4, 6, 18, and 25h on a Waters HPLC-MS system using a SunFire analytical C18 column (5 μ m; 4.6 $\times$ 50 mm) using a stepwise gradient [11: { 10 % [(MeCN + 0.1% TFA) in (water + 0.1% TFA)] for 1 min.; 30 % for 1 min.; 50 % for 4 min.; 70 % for 1.5 min.; and 98 % for 1.5 min.}; Ethacrynic acid: { 10 % [(MeCN + 0.1% TFA) in (water + 0.1% TFA)] for 1 min.; 30 % for 1 min.; 50 % for 4 min.; 70 % for 1.5 min.; and 98 % for 1.5 min.}]. The percentage remaining for each compound relative to the starting amount of compound at 0 h was calculated from the area under the curve (AUC) at different time points and plotted.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors would like to thank Michaela Stumpf, Beate Hecker, and Elisabeth Fischer for their excellent technical assistance. The study was supported by the NIH (1R21AI082434-01) to LB, the Deutsche Forschungsgemeinschaft (BE 1540/18-1) to KB, and an NIH Molecular Libraries grant (U54 HG005033-03) to the Conrad Prebys Center for Chemical Genomics at the Sanford Burnham Medical Research Institute, one of the comprehensive centers of the NIH Molecular Libraries Probe Production Centers Network (MLPCN).

Abbreviations Used

ADME/T	absorption, distribution, metabolism, excretion, toxicity
AUC	area under the curve
BBB	blood-brain barrier
CBIS	Chemical and Biological Information Systems
EDCI	1-ethyl-3-(3- dimethylaminopropyl) carbodiimide
ESI	electron spray ionization
ex/em	excitation/emission
FAC	final assay concentration
G6P	glucose-6-phosphate
G6PD	glucose-6-phosphate dehydrogenase
hG6PD	human glucose-6-phosphate dehydrogenase
HRMS	high resolution mass spectrometry
HTS	high-throughput screening
IRBC	infected red blood cells

MLSMR	Molecular Libraries Small Molecule Repository
MOI	mechanism of inhibition
PAMPA	parallel artificial membrane permeability assay
<i>PfG6PD</i>	<i>Plasmodium falciparum</i> glucose-6-phosphate dehydrogenase
<i>PfGluPho</i>	glucose-6-phosphate dehydrogenase 6-phosphogluconolactonase
PPP	pentose phosphate pathway
RNAi	RNA interference
SAR	structure-activity relationship
TOF	time-of-flight

References

1. Murray CJL, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD. Global malaria mortality between 1980 and 2010: a systematic analysis. *The Lancet*. 2012; 379:413–431.
2. WHO. World malaria report 2008. 2008. http://whqlibdoc.who.int/publications/2008/9789241563697_eng.pdf
3. Baron JM, Higgins JM, Dzik WH. A revised timeline for the origin of *Plasmodium falciparum* as a human pathogen. *J Mol Evol*. 2011; 73:297–304. [PubMed: 22183792]
4. Tanabe K, Mita T, Jombart T, Eriksson A, Horibe S, Palacpac N, Ranford-Cartwright L, Sawai H, Sakihama N, Ohmae H, Nakamura M, Ferreira MU, Escalante AA, Prugnolle F, Bjorkman A, Farnert A, Kaneko A, Horii T, Manica A, Kishino H, Balloux F. *Plasmodium falciparum* accompanied the human expansion out of Africa. *Curr Biol*. 2010; 20:1283–1289. [PubMed: 20656209]
5. Rodrigues T, Moreira R, Lopes F. New hope in the fight against malaria? *Future Med Chem*. 2011; 3:1–3. [PubMed: 21428820]
6. Hill AV. Vaccines against malaria. *Philos Trans R Soc Lond B Biol Sci*. 2011; 366:2806–2814. [PubMed: 21893544]
7. Murambiwa P, Masola B, Govender T, Mukaratirwa S, Musabayane CT. Anti-malarial drug formulations and novel delivery systems: a review. *Acta Trop*. 2011; 118:71–79. [PubMed: 21439929]
8. Bousejra-El Garah F, Wong MH, Amewu RK, Muangnoicharoen S, Maggs JL, Stigliani JL, Park BK, Chadwick J, Ward SA, O'Neill PM. Comparison of the reactivity of antimalarial 1,2,4,5-tetraoxanes with 1,2,4-trioxolanes in the presence of ferrous iron salts, heme, and ferrous iron salts/phosphatidylcholine. *J Med Chem*. 2011; 54:6443–6455. [PubMed: 21888440]
9. Schlitzer M. Antimalarial drugs - What is in use and what is in the pipeline. *Arch Pharm*. 2008; 341:149–163.
10. Murambiwa P, Masola B, Govender T, Mukaratirwa S, Musabayane CT. Anti-malarial drug formulations and novel delivery systems: A review. *Acta Trop*. 2011; 118:71–79. [PubMed: 21439929]
11. Trape JF. The public health impact of chloroquine resistance in Africa. *Am J Trop Med Hyg*. 2001; 64:12–17. [PubMed: 11425173]
12. Marks F, von Kalckreuth V, Kobbe R, Adjei S, Adjei O, Horstmann RD, Meyer CG, May J. Parasitological rebound effect and emergence of pyrimethamine resistance in *Plasmodium falciparum* after single-dose sulfadoxine-pyrimethamine. *J Infect Dis*. 2005; 192:1962–1965. [PubMed: 16267768]
13. Egan TJ, Kaschula CH. Strategies to reverse drug resistance in malaria. *Curr Opin Infect Dis*. 2007; 20:598–604. [PubMed: 17975410]

14. Gottschall JL, Elliot W, Lianos E, McFarland JG, Wolfmeyer K, Aster RH. Quinine-induced immune thrombocytopenia associated with hemolytic uremic syndrome: a new clinical entity. *Blood*. 1991; 77:306–310. [PubMed: 1898704]
15. Veinot JP, Mai KT, Zarychanski R. Chloroquine related cardiac toxicity. *J Rheumatol*. 1998; 25:1221–1225. [PubMed: 9632091]
16. WHO. Guidelines for the treatment of malaria. 2010. http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf
17. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Arie F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. Artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med*. 2009; 361:455–467. [PubMed: 19641202]
18. Noedl H, Se Y, Sriwichai S, Schaecher K, Teja-Isavadharm P, Smith B, Rutvisuttinunt W, Bethell D, Surasri S, Fukuda MM, Socheat D, Chan Thap L. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. *Clin Infect Dis*. 2010; 51:e82–89. [PubMed: 21028985]
19. Carrara VI, Zwang J, Ashley EA, Price RN, Stepniewska K, Barends M, Brockman A, Anderson T, McGready R, Phaiphun L, Proux S, van Vugt M, Hutagalung R, Lwin KM, Phyo AP, Preechapornkul P, Imwong M, Pukrittayakamee S, Singhasivanon P, White NJ, Nosten F. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. *PLoS One*. 2009; 4:e4551. [PubMed: 19234601]
20. Jortzik E, Mailu BM, Preuss J, Fischer M, Bode L, Rahlfs S, Becker K. Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase: a unique bifunctional enzyme from *Plasmodium falciparum*. *Biochem J*. 2011; 436:641–650. [PubMed: 21443518]
21. Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. *Blood Cells Mol Dis*. 2009; 42:267–278. [PubMed: 19233695]
22. Luzzatto L. Glucose 6-phosphate dehydrogenase deficiency: from genotype to phenotype. *Haematologica*. 2006; 91:1303–1306. [PubMed: 17018377]
23. Cappadoro M, Giribaldi G, O'Brien E, Turrini F, Mannu F, Ulliers D, Simula G, Luzzatto L, Arese P. Early phagocytosis of glucose-6-phosphate dehydrogenase (G6PD)-deficient erythrocytes parasitized by *Plasmodium falciparum* may explain malaria protection in G6PD deficiency. *Blood*. 1998; 92:2527–2534. [PubMed: 9746794]
24. Ruwende C, Khoo SC, Snow RW, Yates SN, Kwiatkowski D, Gupta S, Warn P, Allsopp CE, Gilbert SC, Peschu N, et al. Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. *Nature*. 1995; 376:246–249. [PubMed: 7617034]
25. Atamna H, Pascarmona G, Ginsburg H. Hexose-monophosphate shunt activity in intact *Plasmodium falciparum*-infected erythrocytes and in free parasites. *Mol Biochem Parasitol*. 1994; 67:79–89. [PubMed: 7838186]
26. Preuss J, Jortzik E, Becker K. Glucose-6-phosphate metabolism in *Plasmodium falciparum*. *IUBMB Life*. 2012; 64:603–611. [PubMed: 22639416]
27. Becker K, Koncarevic S, Hunt NH. Oxidative stress and antioxidant defense in malarial parasites. In: Sherman IW, editor. *Molecular Approaches to Malaria*. American Society of Microbiology Press; Washington DC: 2005. p. 365–383.
28. Croke A, Diez A, Mason PJ, Bautista JM. Transient silencing of *Plasmodium falciparum* bifunctional glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase. *The FEBS J*. 2006; 273:1537–1546.
29. Baum J, Papenfuss AT, Mair GR, Janse CJ, Vlachou D, Waters AP, Cowman AF, Crabb BS, de Koning-Ward TF. Molecular genetics and comparative genomics reveal RNAi is not functional in malaria parasites. *Nucleic Acids Res*. 2009; 37:3788–3798. [PubMed: 19380379]
30. Lopez-Barragan MJ, Lemieux J, Quinones M, Williamson KC, Molina-Cruz A, Cui K, Barillas-Mury C, Zhao K, Su XZ. Directional gene expression and antisense transcripts in sexual and asexual stages of *Plasmodium falciparum*. *BMC Genomics*. 2011; 12:587. [PubMed: 22129310]

31. Clarke JL, Scopes DA, Sodeinde O, Mason PJ. Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase. A novel bifunctional enzyme in malaria parasites. *Eur J Biochem.* 2001; 268:2013–2019. [PubMed: 11277923]
32. Clarke JL, Sodeinde O, Mason PJ. A unique insertion in *Plasmodium berghei* glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase: evolutionary and functional studies. *Mol Biochem Parasitol.* 2003; 127:1–8. [PubMed: 12615331]
33. ML276 has been declared a probe via the Molecular Libraries Probe Production Centers Network (MLPCN) and is available through the network, see: <http://mli.nih.gov/mli/>
34. Preuss J, Hedrick M, Sergienko E, Pinkerton A, Mangravita-Novo A, Smith L, Marx C, Fischer E, Jortzik E, Rahlfs S, Becker K, Bode L. High-throughput screening for smallmolecule inhibitors of *Plasmodium falciparum* glucose-6-phosphate dehydrogenase 6-phosphogluconolactonase. *J Biomol Screen.* 2012; 17:738–751. [PubMed: 22496096]
35. Trifilenkov AS, Kobak VV, Salina MA, Kusovkova JA, Ilyin AP, Khvat AV, Tkachenko SE, Ivachtchenko AV. Liquid-phase parallel synthesis of combinatorial libraries of substituted 6-carbamoyl-3,4-dihydro-2H-benzo[1,4]thiazines. *J Comb Chem.* 2006; 8:469–479. [PubMed: 16827558]
36. Worley JW, Ratts KW, Cammack KL. 2-Dialkylphosphonyl- and 2-Alkylidene-3,4-dihydro-3-oxo-2H-1,4-benzothiazines. *J Org Chem.* 1975; 40:1731–1734.
37. Ploemen JH, Van Schanke A, Van Ommen B, Van Bladeren PJ. Reversible conjugation of ethacrynic acid with glutathione and human glutathione S-transferase P1-1. *Cancer Res.* 1994; 54:915–919. [PubMed: 8313381]
38. Koncarevic S, Rohrbach P, Deponte M, Krohne G, Prieto JH, Yates J 3rd, Rahlfs S, Becker K. The malarial parasite *Plasmodium falciparum* imports the human protein peroxiredoxin 2 for peroxide detoxification. *Proc Natl Acad Sci U S A.* 2009; 106:13323–13328. [PubMed: 19666612]
39. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD. Quantitative assessment of antimalarial activity *in vitro* by a semiautomated microdilution technique. *Antimicrob Agents Chemother.* 1979; 16:710–718. [PubMed: 394674]
40. Fivelman QL, Adagu IS, Warhurst DC. Modified fixed-ratio isobologram method for studying *in vitro* interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of *Plasmodium falciparum*. *Antimicrob Agents Chemother.* 2004; 48:4097–4102. [PubMed: 15504827]
41. Cornish-Bowden, A. Introduction to enzyme kinetics. In: Cornish-Bowden, A., editor. *Fundamentals of enzyme kinetics.* 3. Portland Press; London: 2004.
42. Cornish-Bowden, A. Reversible inhibition and activation. In: Cornish-Bowden, A., editor. *Fundamentals of enzyme kinetics.* 3. Portland Press; London: 2004.

Figure 1.
Structural requirements for activity

Figure 2.
General SAR strategy

Figure 3.
Dose response curve for **11** in the *Plasmodium* and human G6PD assays, indicating full selectivity for *PfGluPho*.

Figure 4.
Investigation of chemical reactivity/stability of **11** via GSH adduct formation.

Figure 5.
P. falciparum growth inhibition by **11** of chloroquine-sensitive (A) and chloroquineresistant (B) strains. One representative data set out of two independent experiments is shown. Experiments were performed twice in triplicates, of which the average and standard deviation are given.

Figure 6. Mechanistic characterization of **11** vs. NADP⁺ (A) and G6P (B) for *P/GluPho*. The signal (RFU/sec) was plotted against the compound and NADP⁺ or G6P concentration. One representative data set from two independent experiments is shown. Data points are given as averages of duplicates.

Scheme 1.

Synthesis of **5a** and analogs, conditions: i) ethyl thioglycolate, NaOAc, H₂O, 90 °C; ii) ethyl thioglycolate, triethylamine, MeCN, 85 °C; iii) Fe, HOAc, 80 °C; iv) 2-aminomethyl-1-ethylpyrrolidine, EDCI·HCl, HOBt, Et₃N, CH₂Cl₂, 23 °C; v) aldehyde, Ac₂O, Et₃N, reflux; vi) aldehyde, Ac₂O, Et₃N, reflux; LiOH, MeOH, H₂O, 23 °C.

Scheme 2.

Synthesis of compounds **10–15, 17, 22, 29, 33, 34, 39–42** including **11**, conditions: i) CoCl₂, NaBH₄, THF, 23°C, 53%; 2-aminomethyl-1-ethylpyrrolidine, EDCI·HCl, HOBt, Et₃N, CH₂Cl₂, 23°C, 41%; ii) RNH₂, EDCI·HCl, HOBt, Et₃N, CH₂Cl₂, 23 °C, 13–61%.

Table 1

Structures of active benzothiazinone hits from HTS

Entry	Structure	<i>Pf</i> G6PD IC ₅₀ (μM)
5a		1.75
6		2.56
7		4.42
8		9.30
9		17.9

Table 2SAR of benzothiazinones^a inhibiting *Plasmodium falciparum* glucose-6-phosphate dehydrogenase

5a-j		Potency (μM) Ave. ± S.E.M. (n= 4)	
Compound	R	<i>Pf</i> G6PD Primary Assay	<i>Pf</i> G6PD NADPH Kinetic
5a	2-F	1.73 ± 0.08	1.37
5b	H	8.23 ± 2.11	19.7
6^b	2-Cl	2.56 ± 0.19	3.3
5c	2-Me	5.93 ± 1.59	5.01
5d	2-OMe	9.79 ± 1.13	11.3
5e	3-F	2.35 ± 0.29	4.13
5f	4-F	1.41 ± 0.14	2.06
7^b	4-Me	4.42 ± 0.71	11.6
5g	2,3-difluoro	5.72 ± 1.28	3.89
5h	2,6-difluoro	1.65 ± 0.08	2.61
5i	1-naphthyl	4.28 ± 0.87	4.2
5j	2-naphthyl	2.39 ± 0.28	2.88

^a all compounds represented in this table exhibited an IC₅₀ > 80 μM against human G6PD^b screen hit

Table 3

Necessity of styryl moiety in SAR

Entry	Structure	<i>Pf</i> G6PD IC ₅₀ (μM)
5a		1.73
3d		>80
10		>80

Table 4
SAR of benzothiazinones inhibiting *Plasmodium falciparum* glucose-6-phosphate dehydrogenase

Potency (μM) Ave. $\pm$ S.E.M.	
Entry	R1	R2	Yield %	PfG6PD Primary Assay	PfG6PD NADPH Kinetic	
5a racemic		2-F	19	1.7 $\pm$ 0.1	1.4	
11 R-enantiomer ML276		2-F	32	0.9 $\pm$ 0.0	1.9	
12 S-enantiomer		2-F	28	6.6 $\pm$ 0.2	4.7

Potency (μM) Ave. $\pm$ S.E.M.	
Entry	R1	R2	Yield %	PfG6PD Primary Assay	PfG6PD NADPH Kinetic	
13		2-F	48	3.1 ± 0.4	4.0	
14		2-F	61	>80.0	24.4	
15		2-F	79	5.9 ± 0.6	5.0	

Table 5
SAR of benzothiazinones inhibiting *Plasmodium falciparum* glucose-6-phosphate dehydrogenase

Potency (μM) Ave. ± S.E.M.	
Entry	R1	R2	Yield % ^a	PfG6PD Primary Assay	PfG6PD NADPH Kinetic
16		2-F	P	16.7 ± 0.8	11.2
17		2-F	13	17.5 ± 8.5	38.4
18		3-Cl	P	60.0 ± 8.5	43.6
19		4-OMe	P	>80.0	>80.0
20		H	P	8.8 ± 1.6	18.4
21		2-F	P	7.4 ± 0.7	9.4
22		2-F	28	6.9 ± 0.3	4.8
23		2-Cl	P	16.2 ± 2.1	44.9
24		3-Me	P	14.5 ± 3.8	18.8
25		3,4-(OMe)2	P	60.0 ± 10.0	24.5
26		H	P	>80.0	27.2
27		4-Me	P	>80.0	45.9

^aP: commercially purchased compounds

Table 6

SAR of benzothiazinones inhibiting *Plasmodium falciparum* glucose-6-phosphate dehydrogenase.

Potency (μM) Ave. $\pm$ S.E.M.	
Entry	R1	R2	Yield % ^a	PfG6PD Primary Assay	PfG6PD NADPH Kinetic	
28		2-F	P	9.5 $\pm$ 3.6	11.0	
29		2-F	18	16.2 $\pm$ 2.1	25.2	
30		4-OMe	P	49.7 $\pm$ 13.7	>80.0	
31		2-Cl	P	11.1 $\pm$ 1.3	>80.0	
32		3-Me	P	11.8 $\pm$ 0.4	8.8	
33		2-F	6	21.6 $\pm$ 3.4	24.0	
34		2-F	15	>80.0	>80.0	
35		2-F	P	46.6 $\pm$ 10.0	11.0	
36		2-Cl	P	40.9 $\pm$ 12.5	>80.0	
37		3-OMe	P	>80.0	58.5

Potency (μM) Ave. ± S.E.M.	
Entry	R1	R2	Yield % ^a	Pf/G6PD Primary Assay	Pf/G6PD NADPH Kinetic	
38		4-OMe	P	>80.0	>80.0	
8 ^b		H	P	9.3	22.3	
9 ^b		3-Cl	P	17.9	34.2	
39		2-F	27	22.7 ± 2.1	45.2	
40		2-F	36	45.0 ± 5.3	35.0	
41		2-F	36	>80.0	>80.0	
42		2-F	46	>80.0	67.8	

\$watermark-text

\$watermark-text

\$watermark-text

^aP: commercially purchased compounds^bscreen hit

Table 7Summary of *in vitro* ADME/T properties of *P. falciparum* G6PD inhibitor probe **11**

Aqueous Solubility in pION's buffer (μg/mL) [<i>μM</i>] ^a pH 5.0/6.2/7.4		>126/>126/29.4 [<i>>296/>296/ 69</i>]
Aqueous Solubility in 1x PBS, pH 7.4 (μg/mL) [<i>μM</i>] ^a		71.0 [<i>166</i>]
PAMPA Permeability , Pe (x10 ⁻⁶ cm/s) Donor pH: 5.0 / 6.2 / 7.4 Acceptor pH: 7.4		29 / 737 / 806
BBB-PAMPA Permeability , Pe (x10 ⁻⁶ cm/s) Donor pH: 7.4 Acceptor pH: 7.4		233
Plasma Protein Binding (% Bound)	Human 1 μM /10 μM	98.39 / 97.98
	Mouse 1 μM /10 μM	98.95 / 98.34
Plasma Stability (% Remaining at 3 hrs)	Human/Mouse	90.98 / 80.84
Hepatic Microsome Stability (% Remaining at 1hr) Human/Mouse		60.53 / 37.57
Toxicity Towards Fa2N-4 Immortalized Human Hepatocytes LC ₅₀ (OM)		>50

^aSolubility also expressed in molar units (μM) as indicated in *italicized [bracketed values]*, in addition to more traditional μg/mL units.